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The Asilomar Conference on Mass Spectrometry was
begun in 1980 by Laszlo Tokes, Ron Hass, and Arine
Falick with Mass Spectrometry/Mass Spectrometry as
its topic. The conference is now part of the annual series
sponsored by the ASMS. Held at the Asilomar Confer-
ence Center in Pacific Grove, CA, November 5–9, 1997,
the 1997 topic was Mass Spectrometry and Drug Dis-
covery. Steven A. Carr (SmithKline Beecham Pharma-
ceuticals, King of Prussia, PA) and Bradford W. Gibson
(University of California, San Francisco, CA) were the
Program Chairmen. Now held annually, the Conference
has been held at Asilomar every year except for one in
which it was held in Colorado. The Asilomar Confer-
ence Center is an ideal location for this type of directed-
focus meeting. It is secreted between Monterey and
Carmel on the shore of the Pacific ocean. With its shared
accommodations, group meals, great facilities for after-
meeting discussions, and secluded surroundings, par-
ticipants can immerse themselves in the topic in order
to gain a complete appreciation of the oral and poster
presentations as well as the specific area of science.
As can be seen from the titles in the six oral sessions
and the poster presentations (see below), the meeting
was somewhat divided between the use of mass spec-
trometry for the characterization of biopolymers and
combinatorial chemistry. Both of these areas have a
need for high sample throughput. Biopolymer analyses
are being addressed with the development of microchip
technology for the introduction of relative contamina-
tion-free analytes. The need in combinatorial chemistry
is not so much to analyze the proliferation of samples
but to develop ways to evaluate and manage the large
amounts of data being produced.
Walter Moos (CEO of Mitokor Corporation, formerly
Applied Genetics, San Diego, CA) in a type of keynote
presentation entitled “Biotech & Pharma at the Prover-
bial Crossroads” showed his roots as one of the first
people to champion the use of computer-assisted drug
design, combinatorial chemistry, and high-volume
screening in modern pharmaceutical research and de-
velopment in that, although not stated, Dr. Moos im-
plied that if combinatorial chemists have their way,
they will consume all the matter in the universe to build
their libraries. This was in conjunction with his state-
ments about the vast volume of compounds that must
be synthesized in order to find one that will eventually
reach the market as a successful pharmaceutical prod-
uct. He also made another interesting observation about
the human life span once a treatment/prevention for all
diseases and aging had been found. He said that
actuaries had shown that people would then only have
an average life span of 140 years because they would be
killed as a result of an accident.
Along the lines of sample volume requirements
reported by Dr. Moos was the need for better and faster
computer technology to maintain the volume of data
produced by these massive combinatorial libraries in
Joseph A. Loo’s (Parke-Davis, Ann Arbor, MI) presen-
tation entitled “Monitoring Protein/RNA/Drug Inter-
actions by ESI-MS.” In some respects, it appears that
mass spectrometry has come full circle. In the early
days of GC/MS, the limitation was in managing the
large volume of data. In today’s high sample through-
put that uses microchips and rapid acquisition tech-
niques, the limiting factor is once again computing
power and software design.
There was some discussion regarding instrumenta-
tion developments in the oral sessions; however, the
thrust of the meeting was more toward the results
obtained with mass spectrometry rather than new in-
strumentation. One instrumental point of significance is
the improved performance of electrospray ionization at
low flow rates. Several presenters continued to promote
the benefits of electrospray combined with the Paul ion
trap. Increased sensitivity compared to that obtained on
the same manufacturer’s triple-quadrupole mass-to-
charge ratio analyzer was just one of the many benefits
reported along with structural information that could
be obtained from various stages of MSn. Improvements
in instrumental techniques, such as delayed extraction
for the time-of-flight mass spectrometer, were also
reported.
This meeting was a good mixture of reports on
advances in drug discovery through the use of mass
spectrometry and the development and refinement of
mass spectral techniques to benefit further drug discov-
ery. Gain Dollinger, Chiron Corporation, Emeryville,
CA, pointed out that for a long period in the history of
the role of mass spectrometry in drug discovery, ad-
vancements in the instrumentation and methods were
the driving force behind the developments in the appli-
cations; however, today the application needs drive the
developments of the instrumentation and methods. Jack
Henion supported this philosophy with his statement,
“It is easy to find a needle in a haystack when you have
a magnet” when making reference to the high degree of
specificity obtainable by today’s mass spectral tech-
niques.
From the presentations, it is clear that as biotechnol-
ogy continues to drive the pharmaceutical industry,
mass spectrometry will play an ever-increasing role.
The advancement in desorption ionization techniques
and the increase in sensitivity and specificity have made
techniques such as matrix-assisted laser desorption/
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ionization, electrospray, and atmospheric pressure
chemical ionization benchtop tools for the biotechnolo-
gist. Presenters were equally divided between those
who are only interested in what the mass spectral data
can tell them to aid in the understanding of complex
biological mechanisms and those who are more con-
cerned with how mass spectrometry provides this in-
formation so that they can develop techniques and
instrumentation to address the next set of challenges.
The following oral presentations were made:
James A. McCloskey, University of Utah, Salt Lake
City, UT, “Characterization of Oligonucleotides”
Daniel P. Little, Sequenom, San Diego, CA, “Toward
High Throughput Chip-Based DNA Diagnostics by
Maldi-MS”
Matthias Mann, European Molecular Biology Labo-
ratories, Heidelberg, Germany, “Gene Function via the
Analysis of Multi-Protein Complexes”
Jeffrey Shabanowitz, University of Virginia, Char-
lottesville, VA, “Sequencing Biologically Relevant Pep-
tides at the Sub-Femtomole Level From Complex Mix-
tures”
Catherine Costello, Boston University Medical Cen-
ter, Boston, MA, “MS Approaches to Glycan Analysis:
Coping with Heterogeneity”
Bradford W. Gibson, University of California, San
Francisco, CA, “Structure, Function and Therapeutic
Design: Targeting Carbohydrates in Infectious Dis-
eases”
David J. Harvey, Oxford University, Oxford, UK,
“Characterization of Protein Bound Carbohydrates by
MALDI-MS”
Anne-Marie Strang, Genetics Institute, Andover,
MA, “Characterizing Protein Glycosylation: A General
Strategy Combining and Enhancing HPAEC-PED and
MS”
Mark Hemling, SmithKline Beecham Pharmaceuti-
cals, King of Prussia, PA, “Analyzing the Tidal Wave of
the Future”
Daniel Kassel, CombiChem, San Diego, CA, “Maxi-
mizing the Performance and Throughput of an Auto-
mated LC/MS System for the Characterization and
Purification of Combinatorial Libraries”
Stephen Naylor, Mayo Clinic, Rochester, MN,
“Mechanistic Studies of Noncovalent Complex Forma-
tion by ESI-MS-Role in Preclinical Investigations”
John Gilbert, Merck Research Laboratories, West
Point, PA, “Use of LC-MS/MS for Drug Metabolism
Studies in Support of Drug Discovery”
Walter Moos, CEO, Mitokor Corporation, San Diego,
CA, “Biotech & Pharma at the Proverbial Crossroads”
James Vath, Millennium Pharmaceuticals, Inc., Cam-
bridge, MA, “The Role of Mass Spectrometry in Genom-
ic-Based Drug Discovery”
Reudi Aebersold, University of Washington, Seattle,
WA, “MS-Based Techniques for the Analysis of Biolog-
ical Systems”
Steven A. Carr, SmithKline Beecham Pharmaceuti-
cals, King of Prussia, PA, “Characterizing Post-transla-
tional Modifications in Support of Protein Discovery”
Jack D. Henion, Cornell University, Ithaca, NY, “Re-
vised LC/MS/MS Strategies for Meeting the Demands
of Modern Drug Discovery Timelines”
Barry L. Karger, Northeastern University, Boston,
MA, “New Directions in CE/MS and Microchip/MS”
Gavin Dollinger, Chiron Corporation, Emeryville,
CA, “AS/MS @ ACMS-ASMS: A Practical Guide to
Affinity Selection Mass Spectrometry as Applied to
Drug Discovery”
Robert J. Anderegg, Glaxo-Wellcome, Research Tri-
angle Park, NC, “Taking Another (and Another, and
Another) Look at Bioaffinity Selection/Mass Spectrom-
etry”
Brian Chait, Rockefeller University, New York, NY,
“Rapid Approaches to Protein Identification and Char-
acterization”
Jasna Peter-Katalinic, University of Muenster, Muen-
ster, Germany, “Mass Spectrometry of Carbohydrate-
Protein Interactions”
Joseph A. Loo, Parke-Davis, Ann Arbor, MI, “Mon-
itoring Protein/RNA/Drug Interactions by ESI-MS”
The following posters were presented:
Julian P. Whitelegge, University of California, Los
Angeles, CA, “Electrospray-Ionization Mass Spectrom-
etry of Intact Intrinsic Membrane Receptors”
Margaret M. Sheil, University of Wollongong, Wol-
longong, Australia, “Rapid Determination of the Se-
quence Selectivity of DNA Alkylating Agents”
David Tolson, SmithKline Beecham Pharmaceuticals,
Harlow, UK, “MALDI-TOF Sequencing of RNA Using
Enzymatic and Chemical Methods”
Michael L. Gross, Ragulan Ramanthan, W. Zielinski,
and T. P. Layoff, Washington University, St. Louis, MO,
“Consistency Measures for (Poly)Peptide Pharmaceuti-
cals: Electrospray Ionization Mass Spectrometry of In-
sulins with Deuterium Isotope Exchange”
John T. Stults and David Arnott, Genetech Inc., South
San Francisco, CA, “Protein Differential Display and
Mass Spectrometry Strategies for the Identification of
Disease-Related Proteins”
Murray Hackett, University of Washington, Seattle,
WA, “Determination of Lipid A Modifications by
MALDI-TOF, Tandem Quadrupole and Ion Trap Mass
Spectrometry”
Katalin Medzihradszky, University of California,
San Francisco, CA, “Studies on N-Glycosylation of
Recombinant Factor VIII”
Jason Rouse and Anne-Marie Strang, Genetics Insti-
tute, Andover, MA, “Structural Characterization of En-
dole-Released N-Linked Oligosaccharides by High
PH Anion-Exchange Chromatography Matrix-As-
sisted Laser Desorption/Ionization Post-Source De-
cay Time-of-Flight Mass Spectrometry, and Glyco-
sides Digestion”
D. S. Wagner, H. M. Geyser, C. J. Markworth, and
F. J. Schoeney, Glaxo-Wellcome, Inc., Diversity Sciences
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Department, Research Triangle Park, NC, “Mass Encod-
ing of Combinatorial Libraries”
B. Moldover, J. Cavalcoli, R. Van Bogelen, T. Steven-
son, and J. Loo, Parke-Davis Pharmaceutical Research
Molecular Biology Department, and K. Ogorzalek, R.
Leo, C. Mitchell, and P. Andrew, Department of Chem-
istry University of Michigan, “A New Technology for
High Throughput Proteome Mapping From 2-D Gels”
K. B. Lim, Lin Guo, J. S. Gunn, M. M. Daniels, R. P.
Darveau, M. Hackett, and Samuel Miller, University of
Washington, “Lipid A Modification by Salmonella Ty-
phimurium and Pseudomonas Aeruginosa”
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